Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

Author:

Irving Julie A. E.1,Enshaei Amir1,Parker Catriona A.23,Sutton Rosemary4,Kuiper Roland P.5,Erhorn Amy1,Minto Lynne1,Venn Nicola C.4,Law Tamara4,Yu Jiangyan5,Schwab Claire1,Davies Rosanna1,Matheson Elizabeth1,Davies Alysia1,Sonneveld Edwin6,den Boer Monique L.67,Love Sharon B.8,Harrison Christine J.1,Hoogerbrugge Peter M.69,Revesz Tamas10,Saha Vaskar2311,Moorman Anthony V.1ORCID

Affiliation:

1. Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;

2. Children’s Cancer Group, Institute of Cancer, Faculty of Medical & Human Sciences, The University of Manchester, Manchester, United Kingdom;

3. Royal Manchester Children’s Hospital, Central Manchester University Hospitals Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom;

4. Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia;

5. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands;

6. Dutch Childhood Oncology Group, The Hague, The Netherlands;

7. Department of Paediatric Oncology and Haematology, Erasmus MC–Sophia Children’s Hospital, University Medical Centre, Rotterdam, The Netherlands;

8. Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom;

9. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands;

10. Department of Haematology-Oncology, SA Pathology at Women’s and Children’s Hospital and University of Adelaide, Adelaide, Australia; and

11. Tata Translational Cancer Research Centre, Tata Medical Center, New Town, Kolkata, India

Abstract

Key Points Chromosomal abnormalities predict outcome after relapse in BCP-ALL, and high-risk cytogenetics takes precedence over clinical risk factors. Patients with mutations or deletions targeting TP53, NR3C1, BTG1, and NRAS were associated with clinical high risk and an inferior outcome.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3